Medtronic has commenced the U.S. market launch of its Talent thoracic stent graft on the Xcelerant delivery system for minimally invasive treatment of thoracic aortic aneurysms.

Recently approved by the FDA, the company said the Talent thoracic stent graft, with the new delivery system, is now available to physicians across the U.S.
 
The Talent thoracic stent graft expands the applicability of thoracic endovascular aortic repair to more patients with thoracic aortic aneurysms. The Minneapolis-based Medtronic said the features of the Xcelerant delivery system and the Talent provides a range of sizes; improved ability to track and control deployment for stent graft placement; and high radial force.